Andarine
 | |
| Clinical data | |
|---|---|
| ATC code | none |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| Synonyms | Acetamidoxolutamide; Androxolutamide; GTx-007; S-4 |
| CAS Number |
401900-40-1  |
| PubChem (CID) | 9824562 |
| IUPHAR/BPS | 7849 |
| DrugBank |
DB07423  |
| ChemSpider |
8000309 |
| ChEMBL |
CHEMBL125236 |
| Chemical and physical data | |
| Formula | C19H18F3N3O6 |
| Molar mass | 441.357 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| (what is this?) (verify) | |
Andarine (GTx-007, S-4) is an investigational selective androgen receptor modulator (SARM) developed by GTX, Inc for treatment of conditions such as muscle wasting, osteoporosis and benign prostatic hypertrophy,[1] using the non-steroidal androgen antagonist bicalutamide as a lead compound.[2]
Andarine is an orally active partial agonist for androgen receptors. It is less potent in both anabolic and androgenic effects than other SARMs. In an animal model of benign prostatic hypertrophy, andarine was shown to reduce prostate weight with similar efficacy to finasteride, but without producing any reduction in muscle mass or anti-androgenic side effects.[3] This suggests that it is able to competitively block binding of dihydrotestosterone to its receptor targets in the prostate gland, but its partial agonist effects at androgen receptors prevent the side effects associated with the anti-androgenic drugs traditionally used for treatment of BPH.[4]
See also
References
- ↑ Hott, J. L.; Borkman, R. F. (1989). "The non-fluorescence of 4-fluorotryptophan". The Biochemical journal. 264 (1): 297–9. doi:10.1124/jpet.102.040840. PMC 1133577
. PMID 2604714. - ↑ Chen, J; Kim, J; Dalton, J. T. (2005). "Discovery and therapeutic promise of selective androgen receptor modulators". Molecular interventions. 5 (3): 173–88. doi:10.1124/mi.5.3.7. PMC 2072877. PMID 15994457.
- ↑ GGao, W; Kearbey, J. D.; Nair, V. A.; Chung, K; Parlow, A. F.; Miller, D. D.; Dalton, J. T. (2004). "Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: New approach for benign prostate hyperplasia". Endocrinology. 145 (12): 5420–8. doi:10.1210/en.2004-0627. PMC 2098692. PMID 15308613.
- ↑ Gao, W; Kim, J; Dalton, J. T. (2006). "Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands". Pharmaceutical Research. 23 (8): 1641–58. doi:10.1007/s11095-006-9024-3. PMC 2072875. PMID 16841196.